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Background
MRI has dramatically changed the way we diagnose dis-
ease. With the introduction of contrast agents specifi-
cally for MRI, we were now able to see that which was
‘invisible’. Gadopentetate dimeglumine (Magnevist®) was
introduced over 20 years ago, since then many more
agents with variable features have been introduced. Sev-
eral newer agents have improved ‘relaxivity’ and some
designated for organ specify use. Along with the
increased administration of these agents, has been the
emergence of an associated disease complex, Nephro-
genic Systemic Fibrosis (NSF). This is an issue only in
severely impaired renal function patients(eGFR<30 mL/
min/1.73 m2). With increased understanding, the inci-
dence of NSF has plummeted. Some agents such as
MultiHance® (gadobenate dimeglumine) have never had
a single episode of NSF. Most recently a ‘new’ issue
with gadolinium-based contrast agents has emerged;
intracranial gadolinium deposition appearing presumably
late only after multiple contrast MRI’s. McDonald and
Radbruch, noted gadolinium in pts’ brain tissue espe-
cially in the globus pallidus, thalamus, dentate nucleus
and pons in pts with at least four contrast exams. More
troubling, as opposed to NSF, this finding was found in
pts with preserved GFR (eGFR≥49 mL/min/ 1.73 m2).
Objective
To perform a real-world temporal analysis of the fre-
quency in which >4 cumulative doses of gadolinium was
administered.
Methods
We performed a retrospective examination of our CMR
studies to assess the usage of gadolinium (MultiHance)
and frequency of exposure to multiple doses normalized
by weight. In all cases, we used a weight based dosing
formula. Accordingly, we have the following clinical
examples for doses showing various administrations:
Doseage=(Kg)(0.1/Kg)(1 ml/0.5 mmol) or simply:
Doseage=(Kg)(0.2 ml) for a single dose. Figure 1.
Results
For ~2000 patients given MultiHance (2010-2015),
Figure 1 shows the range of gadolinium exposures,
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revealing a non-Gaussian distribution. In Figure 2, we
show a near-Gaussian distribution of dose amounts,
peaking at 25 ml.
Discussion
In our experience, only a small percentage of pts received
multiple doses of gadolinium, with ≥4 exposures repre-
senting only 0.65% (13/1982) of the sampled population.
Assuming similar practice patterns as our high-referral
CMR center, the 100+ million doses world-wide pts
exposed to gadolinium each year, we suggest that a similar
percentage, 0.65%, would receive multiple exposures (>4),
and they represent a sufficiently small population that
could be followed on a society-wide initiative to better
understand brain deposition significance.
Conclusions
Given the available information in this newly ‘discovered
entity’ and assuming this has clinical relevance, until a
‘better’ MRI agent can be found, gadolinium agents still
remain the best modality for optimizing clinical diag-
noses for MRI sequences. This is especially evident in
CMR where infiltrative diseases, MI’s and other cardio-
myopathies are optimized utilizing these contrast agents.
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